T23	Exp 204 238	the cyto-differentiating treatment
T24	Exp 340 377	the retinoic acid receptor type alpha
T25	Exp 403 459	the leukemia-specific t(15;17) chromosomal translocation
T26	Exp 461 463	We
T27	Exp 474 478	that
T28	Exp 989 993	that
T29	Exp 809 821	the compound
T30	Exp 887 897	the levels
T31	Exp 1135 1149	the expression
T32	Exp 1186 1205	the HL-60 cell line
T33	Exp 1257 1277	the peripheral blood
T34	Exp 1326 1342	the stable phase
T35	Exp 1346 1357	the disease
T36	Exp 1153 1182	these differentiation markers
T37	Exp 1556 1560	that
T38	Exp 1668 1673	which
T39	Exp 1608 1622	the expression
T40	Exp 1537 1550	These results
T41	Exp 1801 1805	that
T42	Exp 1774 1794	the normal RAR alpha
T43	Exp 1847 1861	both receptors
T44	Exp 1875 1887	the presence
T45	Exp 1900 1922	the synthetic retinoid
T46	Exp 2017 2037	the natural retinoid
T47	Exp 2051 2063	the presence
T48	Exp 2133 2174	the strong cyto-differentiating potential
R4	Coref Anaphora:T28 Antecedent:T49
R5	Coref Anaphora:T38 Antecedent:T50
T51	SPAN 1762 1794	PML-RAR and the normal RAR alpha
R6	Coref Anaphora:T43 Antecedent:T51
T1	Protein 311 318	PML-RAR
T2	Protein 344 377	retinoic acid receptor type alpha
T3	Protein 379 388	RAR alpha
T4	Protein 548 557	RAR alpha
T5	Protein 762 799	granulocyte colony-stimulating factor
T6	Protein 801 806	G-CSF
T7	Protein 901 931	leukocyte alkaline phosphatase
T8	Protein 933 938	CD11b
T9	Protein 940 944	CD33
T10	Protein 950 964	G-CSF receptor
T11	Protein 1442 1445	LAP
T12	Protein 1472 1480	RAR beta
T13	Protein 1485 1494	RAR gamma
T14	Protein 1674 1681	PML-RAR
T15	Protein 1762 1769	PML-RAR
T16	Protein 1785 1794	RAR alpha
T17	Protein 1891 1898	PML-RAR
T18	Protein 2067 2076	RAR alpha
T19	Protein 2187 2194	PML-RAR
T49	Exp 974 988	concentrations
T50	Exp 1659 1664	cells
